Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05191706 · ClinicalTrials.gov registry record · Phase 4
Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
A Phase 4 study of Cataract, sponsored by EyePoint Pharmaceuticals.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 9
- Study locations
NCT05191706: Recruiting Phase 4 study of Cataract, sponsored by EyePoint Pharmaceuticals.
NCT05191706 is a Phase 4 study of Cataract that is actively recruiting participants, run by EyePoint Pharmaceuticals. The registered enrollment target is 60 participants, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (74% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05191706, a Phase 4 study of Cataract, is actively recruiting participants, sponsored by EyePoint Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 9
- Study locations
Study Summary
A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Prednisolone Acetate Ophthalmic
Study Locations (9)
New York
- EyePoint Investigational Site - Buffalo
- EyePoint Investigative Site - New York
- EyePoint Investigational Site - Rochester
California
- EyePoint Investigational Site - Huntington Beach
- EyePoint Investigational Site - Palo Alto
Massachusetts
- EyePoint Investigative Site - Boston
Mississippi
- EyePoint Investigational Site - Jackson
Nebraska
- EyePoint Investigational Site - Omaha
South Carolina
- EyePoint Investigational Site - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-01-04 |
| Est. Completion | 2026-02 |
| Phase | Phase 4 |
What NCT05191706 shows while recruiting
NCT05191706 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT05191706 lists 9 locations in 6 states (New York, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05191706 about?
NCT05191706 is a clinical study titled "Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract". A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
What is the current status of trial NCT05191706?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2022-01-04. Estimated completion is 2026-02.
What conditions does trial NCT05191706 study?
This clinical trial studies the following conditions: Cataract.
What interventions are being tested in trial NCT05191706?
The interventions under investigation include: Dexamethasone (DRUG), Prednisolone Acetate Ophthalmic (DRUG).
Who is sponsoring clinical trial NCT05191706?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05191706 being conducted?
This trial has 9 study locations across California, Massachusetts, Mississippi, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05191706's enrollment target sits among peer trials
60 54th of 83 higher than 30 of 83 other Cataract trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cataract trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population
RECRUITING · Phase 4
-
A Prospective, Randomized, Subject and Vision-assessor Masked, Multicenter Study Comparing Bilateral Clareon PanOptix, Bilateral Clareon PanOptix Pro, and Mixed Clareon PanOptix Pro/Vivity Intraocular Lens Implantation in Cataract Subjects
RECRUITING · Phase 4
-
Evaluation of a Monofocal Intraocular Lens
RECRUITING · Phase 4
-
Odyssey Evaluation in Post LASIK Patients
RECRUITING · Phase 4
-
Dropless vs. Standard Drops Contralateral Eye Study
COMPLETED · Phase 4
-
Evaluation of Effective Lens Position With a Uniplanar Bi-aspheric IOL
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI